The addition of evolocumab vs ezetimibe to statin therapy for coronary plaque regression and sd-LDL reduction in patients with ultrahigh-risk ASCVD. // Journal of Clinical Lipidology. – URL: https://www.sciencedirect.com/science/article/pii/S1933287426004770?dgcid=rss_sd_all
The addition of evolocumab vs ezetimibe to statin therapy for coronary plaque regression and sd-LDL reduction in patients with ultrahigh-risk ASCVD. Journal of Clinical Lipidology. https://www.sciencedirect.com/science/article/pii/S1933287426004770?dgcid=rss_sd_all
“The addition of evolocumab vs ezetimibe to statin therapy for coronary plaque regression and sd-LDL reduction in patients with ultrahigh-risk ASCVD.” Journal of Clinical Lipidology.
@article{article53022,
title = {The addition of evolocumab vs ezetimibe to statin therapy for coronary plaque regression and sd-LDL reduction in patients with ultrahigh-risk ASCVD},
journal = {Journal of Clinical Lipidology},
url = {https://www.sciencedirect.com/science/article/pii/S1933287426004770?dgcid=rss_sd_all}
}